Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

11.62EUR
4:35pm BST
Change (% chg)

€0.06 (+0.52%)
Prev Close
€11.56
Open
€11.42
Day's High
€11.64
Day's Low
€11.18
Volume
29,811
Avg. Vol
42,955
52-wk High
€27.18
52-wk Low
€9.52

Latest Key Developments (Source: Significant Developments)

Celyad Announces Strategic Updates To The Autologous R/R Aml And Mds Program
Monday, 1 Jul 2019 

July 1 (Reuters) - Celyad SA ::CELYAD ANNOUNCES STRATEGIC UPDATES TO THE AUTOLOGOUS R/R AML AND MDS PROGRAM.CELYAD SA - FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION TO COMMENCE CLINICAL TRIALS FOR NEXT-GENERATION, CAR-T CANDIDATE, CYAD-02.CELYAD SA - FDA AND FAMHP ACCEPTED PROPOSAL TO UTILIZE NEW, PROPRIETARY 'OPTIMAB' MANUFACTURING PROCESS FOR BOTH CYAD-01 AND CYAD-02.  Full Article

Celyad Updates On Cyad-01
Monday, 17 Jun 2019 

June 17 (Reuters) - Celyad SA ::CELYAD PRESENTS CLINICAL UPDATE FOR CYAD-01 AT 24TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION.PRELIMINARY DATA FROM COHORT 10 OF THINK TRIAL EVALUATING DENSER SCHEDULE OF INFUSIONS OF CYAD-01 WITHOUT PRECONDITIONING SHOWED BETTER CELL ENGRAFTMENT COMPARED TO BIWEEKLY INJECTIONS OF CYAD-01 WITHOUT PRECONDITIONING.RESULTS FROM ONGOING PHASE 1 THINK AND DEPLETHINK TRIALS EVALUATING CYAD-01 CONTINUE TO SUPPORT THERAPEUTIC CLINICAL DEVELOPMENT OF NKG2D-BASED CAR-T THERAPY PRODUCT CANDIDATE.  Full Article

Celyad Loss For The Year Narrows To 37.4 Million Euros
Thursday, 28 Mar 2019 

March 28 (Reuters) - CELYAD SA ::CELYAD REPORTS BUSINESS UPDATE AND FULL YEAR 2018 FINANCIAL AND OPERATING RESULTS.FY REVENUE EUR 3.1 MILLION VERSUS EUR 3.5 MILLION YEAR AGO.LOSS FOR THE YEAR EUR 37.4 MILLION VERSUS LOSS OF EUR 56.4 MILLION YEAR AGO.WE LOOK FORWARD TO PROVIDING CLINICAL UPDATES FROM BOTH THE PHASE 1 THINK AND DEPLETHINK TRIALS THROUGHOUT 2019.WE LOOK FORWARD TO ADVANCING MULTIPLE SHRNA-BASED CAR-T PRODUCT CANDIDATES TOWARDS THE CLINIC IN 2020.TREASURY POSITION OF €49.7 MILLION ($56.9 MILLION) AT YEAR-END.FY OPERATING LOSS EXCLUDING NON-RECURRING ITEMS EUR 38.2 MILLION VERSUS LOSS OF EUR 26.6MLN YEAR AGO.  Full Article

Celyad Ended Q3 With 55.9 Million Euros In Cash, Cash Equivalents And Short-Term investments
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - CELYAD SA ::ENDED Q3 WITH EUR 55.9 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.CONFIRMS ITS PREVIOUS GUIDANCE THAT EXISTING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS SHOULD BE SUFFICIENT UNTIL MID-2020.  Full Article

Celyad: Update On CYAD-01 Solid Tumor Clinical Program
Friday, 9 Nov 2018 

Nov 9 (Reuters) - CELYAD SA ::STANDALONE CYAD-01 WITHOUT PRECONDITIONING LEADS TO DISEASE STABILIZATION IN THREE OUT OF 11 METASTATIC COLORECTAL CANCER (MCRC) PATIENTS IN THINK PHASE 1 TRIAL.PRELIMINARY SAFETY DATA FROM THINK CYFLU COHORT, EVALUATING CYAD-01 WITH PRECONDITIONING, REMAINS ENCOURAGING WITH IMPROVEMENT IN CYAD-01 KINETICS.OVERALL, FIVE OUT OF SEVEN (71%) PATIENTS ACHIEVED MEANINGFUL DECREASE IN BONE MARROW BLASTS.SHRINK PHASE 1 TRIAL UPDATE: INITIAL ACTIVITY RESULTS ASSESSED BY PATHOLOGICAL RESPONSE CRITERIA SHOWED ALL THREE PATIENTS ACHIEVED AN OBJECTIVE CLINICAL RESPONSE.SHRINK PHASE 1 TRIAL UPDATE: CONCURRENT TREATMENT OF CYAD-01 WITH FOLFOX CHEMOTHERAPY APPEARS TO BE WELL TOLERATED.SHRINK PHASE 1 TRIAL UPDATE: HE EXPANSION OF PERIPHERAL CYAD-01 CELLS WITH A CONCURRENT ADMINISTRATION OF FOLFOX CHEMOTHERAPY IS SIMILAR TO THE ONE OBSERVED WITH THE STANDALONE CYAD-01.SHRINK PHASE 1 TRIAL UPDATE: FULL DATA FROM THE SHRINK PHASE 1 TRIAL ARE EXPECTED IN MID-2019.THINK CYFLU PHASE 1 COHORT UPDATE: TREATMENT WITH CYAD-01 FOLLOWING STANDARD PRECONDITIONING REGIMEN OF CYFLU WAS WELL TOLERATED.THINK CYFLU PHASE 1 COHORT UPDATE: PRELIMINARY TRANSLATIONAL DATA SUGGEST AN IMPROVEMENT IN THE CELL EXPANSION OF CYAD-01 INDUCED BY THE CYFLU PRECONDITIONING..THINK CYFLU PHASE 1 COHORT UPDATE: FULL DATA FROM THE THINK CYFLU PHASE 1 COHORT ARE EXPECTED IN MID-2019..  Full Article

Celyad Appoints Filippo Petti As Chief Financial Officer
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - CELYAD SA ::CELYAD APPOINTS FILIPPO PETTI AS CHIEF FINANCIAL OFFICER.MR. PETTI’S APPOINTMENT WILL BE EFFECTIVE SEPTEMBER 3RD, 2018.MR. JEANMART REMAINING AS AN ADVISOR THROUGH DECEMBER 3(ST), 2018.  Full Article

Celyad Announces FDA Acceptance Of IND Application For CYAD-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FDA ACCEPTANCE OF IND FOR WORLD'S FIRST NON-GENE EDITED ALLOGENEIC CAR-T CLINICAL PROGRAM.CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FIRST OF A FAMILY OF NON-GENE EDITED ALLOGENEIC CAR-T, TARGETING COLORECTAL CANCER TO BUILD ON EXPERIENCE FROM SHRINK AUTOLOGOUS CAR T PROGRAM.  Full Article

Celyad Announces FDA Acceptance Of Ind Application For Cyad-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Celyad SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.  Full Article

Celyad Announces Pricing Of 47.3 Million Dollars Global Offering
Thursday, 17 May 2018 

May 17 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES PRICING OF $47.3 MILLION GLOBAL OFFERING.PRICING OF A GLOBAL OFFERING OF 1,800,000 ORDINARY SHARES.1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE.523,913 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (ADSS) OFFERED IN UNITED STATES, CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE AT PRICE PER ADS OF USD 26.28.  Full Article

Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting
Thursday, 29 Mar 2018 

March 29 (Reuters) - CELYAD SA ::CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018.‍PRECLINICAL STUDY SHOWS ADDING CD28 OR 4-1BB TO CYAD-01 BRINGS NO BENEFIT FOR IN VITRO ACTIVITY OF RECEPTOR​.TO PRESENT UPDATE FROM THINK TRIAL, NEW SHRINK AND LINK TRIALS IN METASTATIC COLORECTAL CANCER​.‍THINK TRIAL: PRELIMINARY EVIDENCE OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CYAD-01) CLINICAL ACTIVITY​.  Full Article